29 February 2024 OCT appoints Lord Mott OBE to its Board Oxford Cannabinoid Technologies Holdings plc (LSE:OCTP), the biotech company developing prescription cannabinoid medicines, is pleased to announce t... Read more
30 January 2024 OCT announces interim results Oxford Cannabinoid Technologies Holdings plc (LSE:OCTP), the biotech company developing prescription cannabinoid medicines, is pleased to announce i... Read more
10 January 2024 OCT files patent applications Oxford Cannabinoid Technologies Holdings plc (LSE: OCTP) is pleased to announce that it has filed a European application in its own name, directed t... Read more
19 December 2023 OCT presents its year in review Oxford Cannabinoid Technologies Holdings plc (LSE: OCTP) is pleased to announce review of the progress that has been made in 2023. Read the full s... Read more
14 November 2023 OCT announces Board appointment Oxford Cannabinoid Technologies Holdings plc (LSE: OCTP), the pharmaceutical company developing prescription cannabinoid medicines, announces the fo... Read more
10 October 2023 OCT announces successful Phase 1 clinical trial results Oxford Cannabinoid Technologies Holdings plc (LSE: OCTP), the pharmaceutical company developing prescription cannabinoid medicines, is pleased to an... Read more
31 August 2023 OCT announces 2023 Final Results Oxford Cannabinoid Technologies Holdings plc (LSE: OCTP), the pharmaceutical company developing prescription cannabinoid medicines, is pleased to an... Read more
27 July 2023 OCT takes pain drug into Phase I, appoints leading pain expert Oxford Cannabinoid Technologies Holdings plc (LSE: OCTP), the pharmaceutical company developing prescription cannabinoid medicines, is pleased to an... Read more